| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999307 | Urologic Oncology: Seminars and Original Investigations | 2016 | 7 Pages |
Abstract
Our initial experience with AA in the routine management of patients with mCRPC demonstrates an efficacy-effectiveness gap compared with clinical trial. Except for PSA response (>50% decline) in patients managed with AA, postchemotherapy results were inferior to phase III studies. This is most likely because of patient selection, which is a typical weakness when transferring results from phase III trials into clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Anita M.D., Stine R.N., Martin Andreas M.D., Ph.D., Klaus M.D., Ph.D.,